Episode 34 - Arielle Smith and How to Get the Most Out of the Pharma Conferences
My guest in this episode is Arielle Smith. Arielle serves as the President of Life Science at Event Cadence which is an event management platform. She was also one of the founding members of Event Cadence. It enables Life Science companies to efficiently plan and manage both industry conferences and internal meetings. Arielle has worked with pharma companies such as Merck, AstraZeneca, Jazz Pharma, Sanofi, and more. Previously, she has worked with Lampire Biological Laboratories and Jefferson Health, which helped her to provide the Healthcare industry with the best all-in-one industry conference solution. She also worked in sales and client management for Paramount-owned Showtime Networks, the company behind award-winning shows like Shameless and Billions. In this discussion, Arielle and I talk about - How to coordinate efforts of multiple team members - How to collect and leverage data for networking and meetings - The logistics of sending multiple employees to industry events - Individual attendees vs a group of employees being sent by companies. This was an interesting chat as it was about the logistics of attending industry events rather than what's being presented at those events. I found my discussion with Arielle very informative and timely considering the kickoff of industry events. I hope you do too. Here's Arielle Smith.
--------
37:12
--------
37:12
Episode 33 - Ray Jordan and Pharmaceutical Industry's Reputation and Image
My guest in this episode is Ray Jordan. Ray is Principal at Putnam Insights. Ray Jordan is a corporate affairs leader and reputational growth driver in healthcare, technology, biotechnology and consumer industries and has worked with or for companies such as Moderna, Amgen, Johnson & Johnson and Pfizer. Ray has been recognized numerous times by industry sources such as PRWeek, and PRovoke Media. He has helped companies get recognized for high reputational status, including in such rankings by FORTUNE, Axios/Harris, Science Magazine, Dow Jones and others. In this candid interview about the pharmaceutical industry's image and reputation, Ray and I talk about: - What an image crisis looks like from a leader's point of view. - The current pharma reputation landscape and the Gallup poll. - Pharma industry wide efforts to address this. - Difference between big and small pharma reputation needs and - The relationship between reputation and market cap. If you're interested in how corporations, particularly pharma companies, manage their public image, reputation, and any public issues, this episode is for you. Here's Ray Jordan.
--------
48:05
--------
48:05
Episode 32 - Vinay Patel and the Invisible Factors Impacting Drug Prices at Pharmacies
My guest in this episode is Vinay Patel. Vinay is a pharmacist executive with over 18 years in the field and founder of MakoRx. He has been involved with health management, community pharmacy operations, and creating pharmacy services. Vinay has worked in various pharmacy settings including national retail, local community, hospital pharmacy, academia, and group medical practices. His efforts now focus on scaling clinical pharmacy services within employer on-site clinics and bringing employers innovative Rx savings programs. Usually, I interview leaders from the pharmaceutical world, but this was the first time I talked to someone about what happens to the drugs after they leave pharma companies. If you're curious about the drug prices in the USA, I guarantee that you'll find this discussion very enlightening. In this chat, Vinay and I talk about - The pharmacy network in the USA - How drugs reach from pharma companies to patients - Why same drugs cost vary at different pharmacies - Why drug prices have increased over the past 20 years - Why pharma companies are not responsible for the drug prices you pay (and who is) - What should the future of pharmacy look like - The role technology will play in drug distribution and - Advice for an aspiring healthcare entrepreneur. This interview with Vinay was as informative and educational as I hoped it would be. I hope you'll appreciate learning about your medicines' supply chain and costs. Here's my guest - Vinay Patel.
--------
42:54
--------
42:54
Episode 31 - Rene Marcotte and Leveraging Data in the Life Science Industry
My guest in this episode is Rene Marcotte. Rene is Senior Vice President Life Sciences at RCM Technologies. Rene has nearly 40 years of experience as a data architect across multiple industries, including Life Sciences for the past 20 years. He has helped to lead and build over 40 data warehouses and analytic solutions, including for some of the largest and smallest pharmaceuticals. In this discussion, Rene and I talk about data aka the digital gold. Some of the topics we discussed are - The evolution of data over last few decades - Change in data hardware size and capabilities - How cloud has democratized the field for small and big companies - Necessity for an early data plan (pay now or pay much more later) - How end users use data to make better decisions and - What someone needs to work in data analytics. Data is a dry subject but Rene can make it interesting as he did in this interview. I hope you find it interesting too. Here's Rene Marcotte.
--------
36:30
--------
36:30
Episode 30 - Dr. Mohit Jain, Biomarkers, and Precision Guided Medicine
My guest in this episode is Dr. Mohit Jain, founder and CSO of Sapient. Dr. Jain is a physician-scientist with more than 20 years of expertise in physiology, computational biology, and mass spectrometry-based bioanalytics. He formed the Jain Laboratory at UCSD, where he led his team to develop next-generation mass spectrometry systems to probe the non-genetic landscape of disease across large-scale human studies. He founded Sapient in 2021 as a spinout of the Jain Laboratory to expand upon this mission, providing bespoke services multi-omics biomarker discovery. In this wide ranging yet focused interview, we discuss - Biomarkers and how their role has changed - The predictor for a clinical trial success - Precision guided medicine - The change in disease classification over last 20 years - Genetic vs non-genetic reasons for disease - Next generation mass spectrometry and - Different disease expression in different people I enjoyed my chat with Dr. Jain, particularly his ability to simplify complex problems the pharma industry is facing and what should be done about it. Hope you do too. Here's Dr. Mohit Jain.
The Future of Pharma with ISPE Boston.
Find out where the pharmaceutical industry is headed and what it means for you. Join host Samir Gondalia as he chats with the thought leaders of the pharma world about the new technologies, innovative applications and emerging markets and how it’s going to influence the future of Pharma.
Listen to The Future of Pharma, Nothing much happens: bedtime stories to help you sleep and many other podcasts from around the world with the radio.net app
New Zealand